Skip to main content
Dr Ruchira Karunadasa
Authored on 6 Jul 2022 by Dr Ruch Karunadasa,Medically reviewed 8 May 2026 by Adeel Arshad.Next review due: 8 May 2027

The Obesity Epidemic

At a time when the obesity epidemic continues to affect millions in the UK and worldwide, pharmaceutical innovation and clinical services have moved decisively toward GLP-1 weight loss in the UK and related therapies. This article sets out the public health picture, the role of Wegovy and Mounjaro as NICE-approved options where criteria are met, and how private weight management in 2026 can complement NHS pathways.

The obesity epidemic and health risks

Excess weight increases the risk of a number of medical conditions, such as high blood pressure, high cholesterol, heart disease and some cancers. Obesity is also associated with reduced fertility, an increase in mental health problems and numerous joint and mobility problems.

How it works

Get personalised care
02.Get personalised care

We'll provide you with a tailored treatment plan from a UK registered doctor

Get next day delivery
03.Get next day delivery

Receive genuine medication shipped discreetly to your door

Did you know?

Over 40% of the population has tried to lose weight at some point in the last 5 years – so you're certainly not alone